98%
921
2 minutes
20
Multiomic profiling can reveal population heterogeneity for both health and disease states. Obesity drives a myriad of metabolic perturbations and is a risk factor for multiple chronic diseases. Here we report an atlas of cross-sectional and longitudinal changes in 1,111 blood analytes associated with variation in body mass index (BMI), as well as multiomic associations with host polygenic risk scores and gut microbiome composition, from a cohort of 1,277 individuals enrolled in a wellness program (Arivale). Machine learning model predictions of BMI from blood multiomics captured heterogeneous phenotypic states of host metabolism and gut microbiome composition better than BMI, which was also validated in an external cohort (TwinsUK). Moreover, longitudinal analyses identified variable BMI trajectories for different omics measures in response to a healthy lifestyle intervention; metabolomics-inferred BMI decreased to a greater extent than actual BMI, whereas proteomics-inferred BMI exhibited greater resistance to change. Our analyses further identified blood analyte-analyte associations that were modified by metabolomics-inferred BMI and partially reversed in individuals with metabolic obesity during the intervention. Taken together, our findings provide a blood atlas of the molecular perturbations associated with changes in obesity status, serving as a resource to quantify metabolic health for predictive and preventive medicine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115644 | PMC |
http://dx.doi.org/10.1038/s41591-023-02248-0 | DOI Listing |
BMC Cancer
September 2025
Department of Gastrointestinal Surgery, Affiliated Hospital of Chengde Medical University, No. 36 Nanyingzi Street, Chengde, Hebei, 067000, China.
Obes Surg
September 2025
Clinique Mutualiste de Pessac, Pessac, France.
Background: Preoperative treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before bariatric surgery has not been studied. Therefore, we investigated the impact of neoadjuvant treatment with GLP-1 RAs on weight loss and postoperative outcomes in patients who underwent sleeve gastrectomy for severe obesity.
Method: A retrospective single-center study was conducted between January 2022 and December 2023.
Obes Surg
September 2025
E-Da Hospital, Kaohsiung City, Taiwan.
Background: We retrospectively evaluated the efficacy of using additional obesity management medications (OMMs) within the first year after undergoing laparoscopic sleeve gastrectomy (LSG).
Methods: We retrospectively analyzed 246 patients who underwent primary LSG in our institution and were followed up for at least 12 months. We collected body weights preoperatively and at three, six, 12, and 24 months postoperatively, along with body composition and laboratory results preoperatively and at 12 months.
World J Urol
September 2025
Bichat Claude Bernard Hospital, Public Assistance of Paris Hospitals, Paris, France.
Purpose: Screening and diagnosing ISUP ≥ 2 prostate cancer is challenging. This study aimed to determine whether canine detection could be beneficial addition to the ISUP ≥ 2 prostate cancer diagnostic protocol by creating a decision-making algorithm for men with suspected prostate cancer.
Methods: We conducted a prospective study at two urology institutions and a French veterinary school, including men with a suspicion of prostate cancer from November to April 2023, which were divided into two groups according to their prostate biopsy results.
Eur J Nutr
September 2025
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, PO Box 1627, 70211, Kuopio, Finland.
Purpose: To investigate how a group-based lifestyle intervention affects food choices and if the dietary patterns at the end of the intervention are associated with incidence type 2 diabetes (T2D). We also investigated if the possible associations between diet and T2D risk were modified by the genetic risk for T2D.
Methods: Participants in the T2D-GENE study were men with prediabetes aged 50-75 years, body mass index ≥ 25 kg/m, belonging in either low or high genetic risk score (GRS) tertile for T2D.